PUBLISHED ON: May 3, 2010 | Duration: 2 min, 39 sec
The year-long wait for Glenmark Pharmaceuticals to cut a licencing deal is finally over. The company partners with Sanofi-Aventis to develop and commercialise Glenmark's novel molecules for pain treatment led by GRC 15300
